Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies

Next Previous
Search
Trial Profile

A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HMBD 002 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Hummingbird Bioscience

Most Recent Events

  • 18 Apr 2025 Status changed from recruiting to active, no longer recruiting.
  • 23 Oct 2024 Planned number of patients changed from 240 to 313.
  • 23 Oct 2024 Planned End Date changed from 1 Jan 2025 to 1 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top